ADVFN - Advanced Financial Network.
HOME» LSE » G » GSK Share Price » GSK Share News

Glaxosmithkline Share News

 Glaxosmithkline Share Price
GSK Share Price
 Glaxosmithkline Share Chart
GSK Share Chart
 Glaxosmithkline Share News
GSK Share News
 Glaxosmithkline Company Information
GSK Company Information
 Glaxosmithkline Share Trades
GSK Share Trades
 Glaxosmithkline Share Message Board
GSK Share Message Board

GlaxoSmithKline to close Crawley factory in Sussex, 493 jobs to go

LONDON (Thomson Financial) - GlaxoSmithKline PLC. has announced hundreds of people will lose their jobs when it closes its factory in Sussex in 2011, the BBC reported citing a company spokesman. Some 493 people are expected to be affected when the multinational drugs company's Crawley site closes. The company blamed the closure on "declining volumes, regulatory delays and patent expiries". A spokesman said production at the site would continue until the products had been moved to alternative facilities. The spokesperson said: "GSK sincerely regrets the potential impact of this proposal in terms of job losses and will do all it can to help staff through this difficult period. "Implementation of this proposal will be subject to consultation with trade union and staff representatives at the Crawley site. This process will begin immediately." The factory currently produces medicines to treat Parkinson's disease, heart disease, HIV/AIDS, bacterial skin infections, depression, and hypertension. tf.TFN-Europe_newsdesk@thomsonreuters.com slm COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

Share News for Glaxosmithkline (GSK)
DateTimeHeadline
28/08/201515:14:00GlaxoSmithKline PLC Director/PDMR Shareholding
27/08/201512:31:00GlaxoSmithKline PLC Director/PDMR Shareholding
21/08/201514:30:00Pfizer Late-Stage Meningitis B Drug Studies Meet Endpoints
21/08/201514:26:00Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis
21/08/201514:19:00Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update
21/08/201514:16:00Pfizer Late-Stage Meningitis B Drug Studies Meet Endpoints
21/08/201511:20:00Glaxo Sells Drug Rights to Novartis
21/08/201511:04:00Glaxa Sells Rights to Auto-Immune Drug to Novartis
21/08/201507:19:00GSK to Sell Rights in Ofatumumab for Auto-Immune Indications...
21/08/201507:00:00GlaxoSmithKline PLC GSK to divest ofatumumab - auto-immune indications
21/08/201506:42:29Glaxo Sells Ofatumumab Auto-Immune Indication Rights To Novartis
14/08/201516:49:47GlaxoSmithKline PLC Director/PDMR Shareholding
13/08/201502:10:50Glaxo Finds No Legionnaires' Risk at North Carolina Plant
13/08/201500:47:25GlaxoSmithKline Finds No Legionnaires' Risk at North Carolina...
12/08/201515:32:11GlaxoSmithKline PLC Director/PDMR Shareholding
12/08/201509:39:06PRESS: Glaxo Closes Plant Amid Legionnaire's Disease Fears...
12/08/201502:20:06Glaxo Closes Plant After Finding Legionnaires' Bacteria
11/08/201510:25:00IN THE KNOW: Berenberg Increases Glaxo Price Target But Keeps...
07/08/201506:14:59Glaxo Gets Canadian Approval For Asthma Treatment BREO ELLIPTA
05/08/201515:41:16GlaxoSmithKline PLC Director/PDMR Shareholding

Glaxosmithkline Plc and other London Stock Exchange share prices are delayed by at least 20 minutes.
All other share price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad